These recommendations closely align with those of the American Society of Anesthesiologists (June 28-2023)
Concomitant ICV administration of GLP- 1 and GIP significantly reduced food intake, body weight, and alcohol consumption
The active compound is tirzepatide, a synthetic peptide that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R)
To make things worse, added weight increases inflammation
When discussing GLP-1 obesity treatment with patients, it is helpful to frame benefits in terms of overall health gains, not just glucose numbers
For higher concentrations, some protocols utilize a small percentage of DMSO or Ethanol before aqueous dilution